A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Human Serum Albumin/Human Granulocyte-Colony Stimulating Factor(I) Fusion Protein for Injection (GW003) in Patients With Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Balugrastim (Primary)
- Indications Neutropenia
- Focus Adverse reactions
- Sponsors Jiangsu T-mab BioPharma
- 15 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Sep 2017.
- 15 Aug 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2017.
- 13 Jan 2017 Planned End Date changed from 1 Nov 2016 to 1 Jun 2017.